Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/dth.14845 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pemphigus relapse: Mechanisms, risk factors, and agents associated with disease recurrence.
J Dermatol
December 2024
Department of Dermatology, Rutgers Robert Wood Johnson Medical School, Somerset, New Jersey, USA.
Pemphigus represents a spectrum of potentially life-threatening autoimmune-mediated skin blistering conditions caused by antibody production against desmoglein 1 and 3 (anti-DSG 1 and 3) in keratinocytes. Greater than 50% of pemphigus patients experience relapse, which complicates long-term medical management, including risks associated with re-treatment and complications such as infection and dehydration. This review aims to elucidate mechanisms, risk factors, and medications associated with pemphigus relapse.
View Article and Find Full Text PDFTargeting Bruton's tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments.
Adv Rheumatol
August 2024
Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Article Synopsis
- BTK, or Bruton's tyrosine kinase, is crucial for transmitting signals in cells, especially B and T immune cells, affecting their growth and survival.
- Various BTK inhibitors are being researched for treating immune disorders and blood cancers, with ongoing clinical trials exploring their effectiveness.
- The article reviews how these inhibitors work, discusses recent findings in autoimmune and inflammatory diseases, and addresses potential side effects and patient risks associated with their use.
Comparison of the Clinical Efficacy of Rituximab Infusion and Dexamethasone-Cyclophosphamide Pulse Therapy and Their Effect on Serum Th1, Th2, and Th17 Cytokines in Pemphigus Vulgaris-A Prospective, Nonrandomized, Comparative Pilot Study.
Indian Dermatol Online J
April 2024
Department of Biostatistics, AIIMS, New Delhi, India.
Background: Rituximab infusion and dexamethasone-cyclophosphamide pulse (DCP) are the two most popular regimens used in pemphigus vulgaris (PV) in India.
Objective: The present study compared the clinical efficacy of rituximab and DCP in Indian PV patients and their effects on serum Th1,2, and 17 cytokine levels.
Materials And Methods: A total of 37 patients received DCP (Group A, = 22) or rituximab (Group B, rheumatoid arthritis protocol ( = 15)) as per patients' preference.
Clinical and immunological predictors of post-rituximab paradoxical pemphigus flare: A prospective cohort study.
Indian J Dermatol Venereol Leprol
January 2025
Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.
Background Paradoxical flare of pemphigus following rituximab infusion has been reported previously, however, its incidence or risk factors have not been studied in detail. Objectives To evaluate the clinical and immunological predictors associated with post-rituximab paradoxical pemphigus flare. Materials and Methods This was a prospective cohort study including adult patients with pemphigus vulgaris or foliaceus who were treated with rituximab.
View Article and Find Full Text PDFArticle Synopsis
- Rituximab, commonly used to treat pemphigus vulgaris, may trigger psoriasis in some patients, especially those with a prior history of psoriasis.
- Medical professionals should be aware of the potential skin-related side effects of rituximab to better identify and manage these complications.
- The text highlights a case study of a 48-year-old patient who developed psoriatic lesions after receiving rituximab treatment, emphasizing the need for caution in prescribing this medication.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!